Acid-Suppressive Medication and Antimicrobial Use in Infancy Associated with Food Allergy and Anaphylaxis
New research shows infants exposed to acid-suppressive medication had nearly a 6-fold increased risk of food allergy MILWAUKEE, Feb. 6, 2024 /PRNewswire-PRWeb/ -- Patients who were prescribed proton pump inhibitors (PPIs) in infancy demonstrated increased food allergy risk, according to... (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - February 6, 2024 Category: Pharmaceuticals Tags: SVY TRI Source Type: news
[Ad hoc announcement pursuant to Art. 53 LR] Roche exceeds guidance and achieves sales growth of 1% (CER) for 2023 despite sharp COVID-19 sales decline
Group salesgrow by 1%1 at constant exchange rates (CER; -7% in CHF), more than offsetting the decline in COVID-19-related sales and biosimilar erosion, and thereby exceeding 2023 guidanceExcluding COVID-19 products,Group sales increase by 8%Pharmaceuticals Divisionsalesincrease by 6% (excluding COVID-19 medicine Ronapreve: +9%) due to ongoing high demand for newer medicines, with eye medicine Vabysmo continuing to be the top growth driver, followed by Ocrevus (multiple sclerosis), Hemlibra (haemophilia A) and Polivy (blood cancer)Diagnostics Division salesare 13% lower due to high demand for COVID-19 tests in 2022; strong ...
Source: Roche Media News - February 1, 2024 Category: Pharmaceuticals Source Type: news
[Ad hoc announcement pursuant to Art. 53 LR] Roche exceeds guidance and achieves sales growth of 1% (CER) for 2023 despite sharp COVID-19 sales decline
Group salesgrow by 1%1 at constant exchange rates (CER; -7% in CHF), more than offsetting the decline in COVID-19-related sales and biosimilar erosion, and thereby exceeding 2023 guidanceExcluding COVID-19 products,Group sales increase by 8%Pharmaceuticals Divisionsalesincrease by 6% (excluding COVID-19 medicine Ronapreve: +9%) due to ongoing high demand for newer medicines, with eye medicine Vabysmo continuing to be the top growth driver, followed by Ocrevus (multiple sclerosis), Hemlibra (haemophilia A) and Polivy (blood cancer)Diagnostics Division salesare 13% lower due to high demand for COVID-19 tests in 2022; strong ...
Source: Roche Investor Update - February 1, 2024 Category: Pharmaceuticals Source Type: news
Clinical Challenges: Test Your Knowledge of Food Allergies
(MedPage Today) -- A three-question quiz covering our series on different aspects of food allergy management (Source: MedPage Today Allergy)
Source: MedPage Today Allergy - January 31, 2024 Category: Allergy & Immunology Source Type: news
Clinical Challenges: Anaphylaxis and Epinephrine
(MedPage Today) -- Approximately 2% of adults and 4% to 8% of children have food allergies in the U.S., with food-induced anaphylaxis resulting in roughly 30,000 emergency department visits, 2,000 hospitalizations, and 150 deaths each year.
While... (Source: MedPage Today Allergy)
Source: MedPage Today Allergy - January 31, 2024 Category: Allergy & Immunology Source Type: news
University of Chicago Study Determines Certain Gut Bacteria Can Help Prevent Food Allergies and Other Gastrointestinal Illnesses
With further research, clinical laboratories may soon be performing macrobiotic testing to measure certain bacterial levels in patients’ gut bacteria New insights from the University of Chicago (UChicago) into how human microbiota (aka, gut bacteria) play a role in food allergies has the potential to change the way a number of gastrointestinal health conditions are […]
The post University of Chicago Study Determines Certain Gut Bacteria Can Help Prevent Food Allergies and Other Gastrointestinal Illnesses appeared first on Dark Daily. (Source: Dark Daily)
Source: Dark Daily - January 19, 2024 Category: Laboratory Medicine Authors: Jillia Schlingman Tags: Laboratory News Laboratory Pathology Laboratory Resources Laboratory Testing Precision Medicine anaphylactic response anatomic pathology antigen Asthma and Allergy Foundation of America butyrate Cathryn Nagler PhD circulatory system Source Type: news
The Battle Over What Medical Equipment Needs to Be on Your Plane
Treatment for a life-or-death midair medical emergency can depend on which plane you happen to be on. More than 20 million Americans are estimated to have food allergies, based on data from the National Center for Health Statistics, yet not every commercial plane is stocked with epinephrine…#epipen (Source: Reuters: Health)
Source: Reuters: Health - January 16, 2024 Category: Consumer Health News Source Type: news
Clinical Challenges: Oral Immunotherapy for Food Allergies
(MedPage Today) -- Hailed for opening a new chapter in food allergy management, oral immunotherapy (OIT) is nevertheless going through growing pains in accessibility and acceptance in clinical practice.
In 2020, the FDA approved peanut allergen... (Source: MedPage Today Allergy)
Source: MedPage Today Allergy - January 10, 2024 Category: Allergy & Immunology Source Type: news
Injected Xolair Therapy Could Prevent Food Allergies in Kids
THURSDAY, Dec. 21, 2023 -- A new treatment appears to reduce food allergies in children and teens, according to interim clinical trial results.
A lab-made monoclonal antibody called omalizumab (Xolair) significantly increased the amounts of common... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - December 21, 2023 Category: General Medicine Source Type: news
How already-approved Genentech drug could attack common — and potentially deadly — food allergies
A 20-year-old allergic asthma drug from Genentech Inc. will get a date with regulators as a potential treatment for people accidental exposed to multiple foods that set off their allergies. (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - December 19, 2023 Category: Pharmaceuticals Authors: Ron Leuty Source Type: news
FDA grants priority review to Xolair (omalizumab) for children and adults with food allergies based on positive National Institutes of Health phase III study results
If approved, Xolair would be the first medicine to reduce allergic reactions to multiple foods following an accidental exposureInterim analysis results from first-of-its-kind phase III OUtMATCH study showed Xolair significantly increased the amount of peanut, milk, egg and cashew it took to cause an allergic reaction17 million people in the U.S. have confirmed food allergies and more than 40% of children and more than half of adults with food allergies have experienced a severe reaction at least once1,2,3Basel, 19 December 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug Administration ...
Source: Roche Media News - December 19, 2023 Category: Pharmaceuticals Source Type: news
FDA grants priority review to Xolair (omalizumab) for children and adults with food allergies based on positive National Institutes of Health phase III study results
If approved, Xolair would be the first medicine to reduce allergic reactions to multiple foods following an accidental exposureInterim analysis results from first-of-its-kind phase III OUtMATCH study showed Xolair significantly increased the amount of peanut, milk, egg and cashew it took to cause an allergic reaction17 million people in the U.S. have confirmed food allergies and more than 40% of children and more than half of adults with food allergies have experienced a severe reaction at least once1,2,3Basel, 19 December 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug Administration ...
Source: Roche Investor Update - December 19, 2023 Category: Pharmaceuticals Source Type: news
McGovern Allergy & amp; Asthma Clinic Is Proud To Announce The Sergio Lopez Food Allergy Awareness Act Passes in Texas
Governor Abbot signs The Sergio Lopez Food Allergy Awareness Act Passes in Texas; The Landmark Legislation Ensures Comprehensive Food Allergen Information in Restaurants Statewide HOUSTON, Dec. 19, 2023 /PRNewswire-PRWeb/ -- A triumphant moment for the food allergy community unfolded on... (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - December 19, 2023 Category: Pharmaceuticals Tags: AVO Source Type: news
FDA grants priority review to Xolair (omalizumab) for children and adults with food allergies
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug Administration (FDA) has accepted, under Priority Review, the company's supplemental Biologics License Application (sBLA) for Xolair® (omalizumab) for the reduction of allergic reactions, including anaphylaxis, that may occur with an accidental exposure to one or more foods in adult and paediatric patients aged 1 year and older with food allergy. (Source: World Pharma News)
Source: World Pharma News - December 19, 2023 Category: Pharmaceuticals Tags: Featured Roche Business and Industry Source Type: news
Bullying in Japanese children and adolescents with food allergies - Kunigami C, Imai T, Yamashita K, Okawa M, Takagi T, Honda A, Okada Y, Maeda M, Kamiya T.
OBJECTIVE: To elucidate the prevailing circumstances of victimization, including bullying, faced by children afflicted with food allergies in Japan. METHODS: From July to August 2021, we executed a web-based questionnaire survey targeting children ... (Source: SafetyLit)
Source: SafetyLit - December 15, 2023 Category: International Medicine & Public Health Tags: Age: Adolescents Source Type: news
